Central Pattaya invites runners from around the world to experience a 5K beach race combining sunset, music, entertainment and Pattaya’s vibrant beach lifestyle on 31 October 2026

PATTAYA, Thailand, Sept. 14, 2026 /PRNewswire/ — Get ready to run Thailand’s most famous beach destination after dark. Central Pattaya, a global beachfront landmark in the heart of Pattaya, invites runners and travelers from around the world to join the ‘Pattaya International Bikini Beach Race 2026: Run the wave. Own the night.‘ on 31 October 2026. Celebrating its 10th anniversary under the theme “The Sunset to Moonlight Beach Race,” the 5K race will bring thousands of runners to the sands of Pattaya Beach for a one-of-a-kind night combining sunset running, music, entertainment and Pattaya’s vibrant beach lifestyle.

Last year, the event attracted more than 5,000 runners from around the world, establishing the Pattaya International Bikini Beach Race as one of Thailand’s most popular and distinctive seaside running events.

This year, runners will take on a 5K course along Pattaya Beach, starting and finishing in front of Central Pattaya. Beginning against a spectacular seaside sunset, the race will continue into the evening as the beachfront transforms into a vibrant moonlight celebration filled with music and entertainment. Taking place on Halloween night, the 2026 edition will bring even more energy to the beach, inviting runners to dress up, stand out and be part of a colorful international running community in the heart of Pattaya.

More than just a race, the event offers international visitors a unique reason to turn race weekend into a Pattaya beach getaway. Runners can experience the city’s beaches alongside its shopping, dining, entertainment and nightlife — all within one of Thailand’s most dynamic seaside destinations.

Event: Pattaya International Bikini Beach Race 2026
Date: Saturday, 31 October 2026
Distance: 5K Beach Run
Location: Pattaya Beach, starting and finishing in front of Central Pattaya
Registration Fee: US$30.49 (THB 1,000)
Registration: Open until 30 October 2026
Click: https://worldsmarathons.com/marathon/pattaya-bikini-run

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that a preclinical research paper evaluating the combination of ATG-037 (CD73 Small Molecule Inhibitor) and selinexor for the treatment of multiple myeloma (MM), conducted in collaboration with the Department of Hematology at Peking University Third Hospital, has been published in Cancer Gene Therapy, an international SCI journal under Springer Nature.

Details of the Paper
Title: CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8⁺ T cells
Journal: Cancer Gene Therapy
DOI: 10.1038/s41417-026-01078-9

Study Design:

The research team first analyzed CD73 expression across multiple tumor cell lines following selinexor treatment, then tested the combination in vivo using a J558-inoculated BALB/c mouse model, with mice divided into a vehicle group, an ATG-037 monotherapy group, a selinexor monotherapy group and a combination-therapy group. Single-cell RNA sequencing was used to characterize immune cell subtypes and tumor-immune crosstalk, immunofluorescence staining was performed on tumor tissue, and a co-culture model of CD8⁺ T cells and multiple myeloma cell lines was established to confirm the mechanism behind the combination’s antitumor effect.

Key Findings: 

Selinexor treatment was found to upregulate CD73 expression in the majority of tumors, a resistance-associated mechanism that the combination approach was designed to counter. In the mouse model, the combination therapy suppressed tumor growth with an inhibition rate of 62%, compared with 31% for ATG-037 monotherapy and 43% for selinexor monotherapy. Single-cell RNA sequencing showed that the combination synergistically potentiated CD8⁺ T cell activation by enhancing the interaction between CD8⁺ T cells and Enpp1⁺ cells via the CD80–CD28 signaling pathway, and the resulting increase in CD8⁺ T cell infiltration into tumor tissue was confirmed by immunofluorescence staining. In co-culture experiments, CD73 inhibition was shown to strengthen selinexor-mediated tumor cell killing by activating CD8⁺ T cells, with significantly elevated levels of Granzyme B (P=0.0252) and IFN-γ (P=0.0067) observed in the combination group.

Conclusion:

The study highlights the synergistic potential of combining selinexor with a CD73 inhibitor for enhancing CD8⁺ T cell-mediated tumor cytotoxicity in MM. Selinexor therapy upregulates CD73 in the TME, driving adenosine accumulation and an immunosuppressive state. Combined use of ATG-037 blocks this immunosuppressive feedback loop via suppression of CD73-dependent adenosine synthesis, restoring CD8⁺ T cell activation and proliferation while enhancing T cell cytotoxicity through activation of the CD80-CD28 costimulatory axis. These findings establish a novel, clinically feasible therapeutic paradigm for addressing drug resistance and refractory MM.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene’s proprietary AnTenGager^® platform.

AnTenGager^®, is Antengene’s proprietary TCE 2.0 platform, featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 34 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

PR / IR Contacts: 
Peter Qian
E-mail: peter.qian@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

Board Authorization Reflects Confidence in Solidion’s Long-Term Strategy and Commitment to Enhancing Shareholder Value

DALLAS, Sept. 14, 2026 /PRNewswire/ — Solidion Technology, Inc. (NASDAQ: STI) (“Solidion Technology” or “the Company”), an advanced battery technology solutions provider, today announced that its Board of Directors (“the Board”) has authorized a new stock buyback program, pursuant to which the Company intended to buyback up to $1.0 Million of the Company’s outstanding common stock.

The stock buyback program became effective on September 13, 2026 and will remain in effect until (i) the date on which the full amount authorized has been repurchased, (ii) March 14, 2028 or (iii) the date on which the authorization is terminated by the Board.

The authorization reflects the Board’s confidence in Solidion’s long-term strategy and provides the Company with additional flexibility in its approach to capital allocation. Solidion believes that the buybacks may represent an attractive use of capital while supporting the Company’s broader objective of creating long-term value for stockholders. Open-market repurchases are expected to be conducted in accordance with applicable federal securities laws, as well as applicable Nasdaq requirements and state law.

“The Board’s authorization of this stock buyback program reflects our confidence in Solidion’s long-term prospects and our commitment to disciplined capital allocation,” said Jaymes Winters, Chief Executive Officer of Solidion Technology. “We believe that our technology, intellectual property and strategic position provide a strong foundation for future growth. This program gives us the flexibility to act when we believe market conditions present an attractive opportunity to invest in Solidion and enhance long-term value for our stockholders.”

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 385 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Please follow us on:

LinkedIn: https://www.linkedin.com/company/solidion-tech
X: https://x.com/solidiontech?lang=en 

CHUZHOU, China, Sept. 14, 2026 /PRNewswire/ — Trina Storage, the energy storage business unit of Trinasolar, has signed a Memorandum of Understanding (MoU) with AMP-lify, a Japanese clean energy platform, to supply approximately 1 GWh of grid-connected battery energy storage system (BESS) equipment for AMP-lify’s projects. AMP-lify develops, constructs and operates grid-connected BESS, utility-scale solar, and onshore wind projects across Japan.

Under the MoU, Trina Storage will supply its Elementa 3 series BESS and provide related technical support for approximately 1 GWh of AMP-lify’s BESS projects. Trina Storage’s Japan team will support system configuration, technical consultation, delivery coordination and after-sales service.

Trina Storage’s Elementa 3 is equipped with Trina Storage in-house 587Ah high-capacity cell, providing up to 6.25 MWh per container for larger utility-scale sites. For projects affected by transport access, limited land or proximity to communities, the 1.56 MWh Elementa 3 Flex offers an approximately five-square-metre footprint, a weight of about 13 tonnes for standard-truck transport, operating noise of 65 dB or less and modular expansion.

Japan’s Seventh Strategic Energy Plan projects renewable energy at approximately 40–50% of power generation in fiscal year 2040 and calls for storage batteries to help balance renewable output. As variable renewable generation increases, developers need storage projects that combine appropriate system design with local execution and long-term support. Trina Storage’s BESS technology and Japan-based support are backed by its recognition as a BloombergNEF Tier 1 energy storage supplier for 11 consecutive quarters.

“Japan’s storage market needs projects that are technically sound and executable under local conditions. Working with Trina Storage’s technology and local support gives us a strong basis to move the projects from site evaluation through construction and into reliable operation,” said Martin Stein, Representative Director and CEO of AMP-lify.

“Japan’s storage market has distinct engineering and delivery requirements. Road weight limits and narrow site access affect transport, while mountainous terrain, limited land, community noise expectations, seismic design and coastal conditions influence system configuration. This MoU allows us to address those factors with AMP-lify from the earliest stages of development. By combining its local execution capabilities with our Elementa 3 portfolio and Japan-based technical support, we can configure each project around its site requirements while building toward the scale envisaged under this cooperation,” said Dr Leo Zhao, Head of Energy Storage, Trinasolar Asia Pacific.